Malek NP - Search Results

1

Editorial: Helicobacter pylori eradication therapy: advantages and disadvantages.

Bien J, Bozko M, Malek NP, Bozko P. Bien J, et al. Among authors: malek np. Curr Pharm Des. 2014;20(28):4487-8. doi: 10.2174/138161282028140704103024. Curr Pharm Des. 2014. PMID: 24998645 No abstract available.

2

Editorial: Gut microbiota and gastrointestinal diseases: to treat or not to treat.

Bien J, Bozko M, Malek NP, Bozko P. Bien J, et al. Among authors: malek np. Curr Pharm Des. 2014;20(28):4533-4. Curr Pharm Des. 2014. PMID: 24998646 No abstract available.

3

Editorial (Thematic Issue: Pathogenetic Mechanisms of CLL - A Target in Therapy).

Bozko M, Podhorecka M, Macheta A, Bozko A, Malek NP, Bozko P. Bozko M, et al. Among authors: malek np. Curr Cancer Drug Targets. 2016;16(8):651. doi: 10.2174/156800961608160902101746. Curr Cancer Drug Targets. 2016. PMID: 27758697 No abstract available.

4

Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy.

Bozko M, Bozko A, Scholta T, Malek NP, Bozko P. Bozko M, et al. Among authors: malek np. Curr Med Chem. 2017;24(15):1487. doi: 10.2174/092986732415170630115722. Curr Med Chem. 2017. PMID: 28728539

5

Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?

Podhorecka M, Macheta A, Bozko M, Bozko A, Malek NP, Bozko P. Podhorecka M, et al. Among authors: malek np. Curr Cancer Drug Targets. 2016;16(8):652-658. doi: 10.2174/1568009616666160427103930. Curr Cancer Drug Targets. 2016. PMID: 27117115 Review.

6

Dysregulation of Carnosine Metabolism in Progression of Diseases.

Bozko M, Drozak J, Malek NP, Bozko P. Bozko M, et al. Among authors: malek np. Curr Med Chem. 2020;27(11):1713. doi: 10.2174/092986732711200423112140. Curr Med Chem. 2020. PMID: 32340600 No abstract available.

7

Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer.

Klein SM, Bozko M, Toennießen A, Malek NP, Bozko P. Klein SM, et al. Among authors: malek np. Curr Med Chem. 2022;29(24):4293-4300. doi: 10.2174/0929867329666220112141211. Curr Med Chem. 2022. PMID: 35023452

8

Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.

El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. El Khatib M, et al. Among authors: malek np. PLoS One. 2013 Oct 30;8(10):e77433. doi: 10.1371/journal.pone.0077433. eCollection 2013. PLoS One. 2013. PMID: 24204826 Free PMC article.

9

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR. Palagani V, et al. Among authors: malek np. PLoS One. 2012;7(10):e46514. doi: 10.1371/journal.pone.0046514. Epub 2012 Oct 19. PLoS One. 2012. PMID: 23094026 Free PMC article.

10

Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression.

Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, Sipos B, Malek NP, Plentz RR. Palagani V, et al. Among authors: malek np. Carcinogenesis. 2014 Apr;35(4):859-66. doi: 10.1093/carcin/bgt394. Epub 2013 Nov 30. Carcinogenesis. 2014. PMID: 24293409

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters